[AF] Los Cox-2

[Pedro del Río Pérez]

Están saliendo tantos datos acerca de los inhibidores de la COX-2
que uno parece incapaz de digerirlos todos por la velocidad a la
que aparecen.
Primero el rofecoxib.
Ahora el celecoxib está en el punto de mira.
Los siguientes COx-2 (aun no comercializados en España) paracen
no tan seguros a tenor de las informaciones que nos están llegando.
Y también parece que le va a tocar al 'viejo' naproxeno que ha sido
puesto bajo vigilancia por aumentar los eventos cardiovasculares
(ver cita al final del correo).

Saludos
................................................
Pedro del Río Pérez
pedrodelrio en usuarios.retecal.es
................................................





Now naproxen? NIH halts Alzheimer's prevention trial after seeing 50% 
increased cardiovascular risk with naproxen

Today's rheumawire news

Dec 21, 2004

Bethesda, MD - People in pain may be starting to wonder if there's anything 
to help alleviate their symptoms: yesterday, the National Institutes of 
Health (NIH) announced that it had suspended the use of both celecoxib 
(Celebrex, Pfizer) and naproxen (Aleve, Bayer) in an Alzheimer's prevention 
large clinical trial after discovering that naproxen appeared to increase 
the risk of cardiovascular (CV) events and stroke by 50% compared with 
patients on placebo.
The celecoxib arm was also suspended, not because of an uptick in CV events 
in the NIH trial, but because of the announcement by Pfizer last week, 
reported by rheumawire, that high doses of its popular arthritis drug 
appeared to increase the risk of CV events in patients participating in a 
cancer trial and taking high doses of the drug.
"This step is being taken as a precautionary measure to ensure the safety of 
the study's participants," NIH director Dr Elias A Zerhouni commented in a 
press release. "The investigators made their decision based on the 
risk/benefit analysis specific to this trial."